>When GTCB is off the ground and running, there is nothing stopping them from persuing the goal of tweaking protein drugs too by developing strains of goats with modified expression of glycosylases and glycosyltransferases in their mammary glands.<
In theory GTC could attempt this, but it’s not in their current plans and it probably won’t be in their future plans, IMO.
There is plenty of business for GTC to seek out by replicating endogenous proteins. Once you start tweaking compounds to improve them, the regulatory hurdles increase by an order of magnitude.
Market Data 
Markets 
AI
